Cite
HARVARD Citation
Kaloyannidis, P. et al. (2020). Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. British journal of haematology. pp. 540-549. [Online].